Sanctura XR to begin Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Indevus is on track to initiate a Phase III program for its once-daily Sanctura (trospium) formulation Sanctura XR this summer, "with a goal of submitting an NDA in the second half of next year," the firm announces June 15. Esprit Pharma is Indevus' new co-promotion partner for the Sanctura overactive bladder therapy brand under a July 1 deal; Pliva had been Indevus' previous marketing partner...
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.